Journal
PEDIATRIC BLOOD & CANCER
Volume 66, Issue 7, Pages -Publisher
WILEY
DOI: 10.1002/pbc.27750
Keywords
acute kidney injury; cefepime; hematology; oncology; infections; piperacillin; tazobactam; vancomycin
Categories
Funding
- NCI NIH HHS [K12 CA090625] Funding Source: Medline
Ask authors/readers for more resources
There is mounting evidence that combination of antibiotic therapy with vancomycin and piperacillin/tazobactam (pip/tazo) is associated with acute kidney injury (AKI). To determine whether vancomycin plus pip/tazo is associated with higher rates of AKI compared to vancomycin plus cefepime among pediatric hematology/oncology (heme/onc) patients, we examined 121 heme/onc patients receiving at least two consecutive days of therapy with vancomycin and either pip/tazo or cefepime. Rate of AKI was higher in the pip/tazo than the cefepime group (4/27 [14.8%] vs 2/94 [2.1%], P = 0.022).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available